Mawei Biologics: Clinical trials on the indication of multiple sclerosis for 9MW5211 injection have been approved.

Mawei Biotech announced that it has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The clinical trial application for 9MW5211 injection for the indication of multiple sclerosis has been approved. In addition, its clinical trial application for the indication of inflammatory bowel disease has been approved by the National Medical Products Administration and FDA respectively. The company is advancing several other clinical trial applications for different indications, some of which have been accepted. Due to the long drug development cycle, multiple approval processes, and high uncertainty factors, investors are reminded to pay attention to the risks.